CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

luspatercept

Last Updated: December 24, 2020
Result type: Reports
Project Number: SR0669-000
Product Line: Reimbursement Review

Generic Name: luspatercept

Brand Name: Reblozyl

Manufacturer: Celgene Inc. / Bristol-Myers Squibb Canada Co.

Therapeutic Area: beta-thalassemia associated anemia

Indications: For the treatment of adult patients with red blood cell (RBC) transfusion-dependent anemia associated with beta(β)-thalassemia

Manufacturer Requested Reimbursement Criteria1: For the treatment of adult patients with -thalassemia associated anemia who require red blood cell (RBC) transfusions.

Submission Type: Initial

NOC Status at Filing: Post NOC

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openOctober 29, 2020
Call for patient/clinician input closedDecember 17, 2020
Clarification:

- Patient input submission received from the Thalassemia Foundation of Canada and Canadian Organization for Rare Disorders (CORD)

Submission receivedNovember 26, 2020
Submission acceptedDecember 10, 2020
Review initiatedDecember 11, 2020
Clarification:

- Selected for CADTH/INESSS Joint Clinician Engagement

Draft CADTH review report(s) provided to sponsor for commentMarch 09, 2021
Deadline for sponsors commentsMarch 18, 2021
CADTH responses on draft review report(s) provided to sponsorApril 09, 2021
Expert committee meeting (initial)April 21, 2021
Draft recommendation issued to sponsorMay 03, 2021
To
May 05, 2021